Multiple candidate biomarkers for amyotrophic lateral sclerosis (ALS) have emerged across a range of platforms. Replication of results, however, has been absent in all but a few cases, and the range of control samples has been limited. If progress toward clinical translation is to continue, the specific biomarker needs of ALS, which differ from those of other neurodegenerative disorders, as well as the challenges inherent to longitudinal ALS biomarker cohorts, must be understood. Appropriate ...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis.
If you are the owner of this record, you can report an update to it here: Report update to this record